• 1
    Evans R III. Epidemiology and natural history of asthma, allergic rhinitis and atopic dermatitis. In: MiddletonEJr, ReedCE, EllisEF, AdkinsonNrJr, YungingerJW, BusseWW, editors. Allergy: principles and practice. St Louis, MO: CV Mosby, 1993:11091136.
  • 2
    Kuna P, Lazarovich M, Kaplan AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:104112.
  • 3
    Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989;19:701705.
  • 4
    Warringa RAJ, Koenderman L, Kok PTM, Kreukniet J, Bruijnzeel PLB. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Blood 1991;77:26942700.
  • 5
    Bousquet J, Chanez P, Campbell AM, et al. Inflammatory processes in asthma. Int Arch Allergy Appl Immunol 1991;94:227232.
  • 6
    Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment. Allergy 1979;44:342348.
  • 7
    Schwibert LA, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996;97:143152.
  • 8
    Schleimer RP. Glucocorticosteroids: their mechanism of action and use in allergic diseases. In: MiddletonEJr, ReedCE, EllisEF, AdkinsonNrJr, YungingerJW, BusseWW, editors. Allergy: principles and practice. St Louis, MO: CV Mosby, 1993:893925.
  • 9
    Basedovsky H, Rey AD, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652654.
  • 10
    Hakanson L, Rak S, Dahl R, Venge P. The formation of eosinophil and neutrophil chemotactic activity during pollen season and after allergen challenge. J Allergy Clin Immunol 1989;83:933939.
  • 11
    Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990;86:706713.
  • 12
    European Academy of Allergology and Clinical Immunology. Skin tests used in type I allergy testing. Position paper. Allergy 1989;44 Suppl 10:159.
  • 13
    Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. New Engl J Med 1985;313:6570.
  • 14
    Venge P. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin Exp Allergy 1993;23:37.
  • 15
    Sher R, Glover A. Isolation of human eosinophils and their lymphocyte-like rosetting properties. Immunology 1976;31:337341.
  • 16
    Durham SR, Kay AB. Eosinophils, bronchial hyperreactivity and late phase asthmatic reactions. Clin Allergy 1985;15:411418.
  • 17
    Snyderman R, Altman LC, Hausman MS, Merghenhagen SE. Human mononuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic factor. J Immunol 1972;108:857860.
  • 18
    Meltzer EO, Orgel HA, Bronsky EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry and nasal cytology. J Allergy Clin Immunol 1990;86:221230.
  • 19
    Linder A, Venge P, Deusch H. Eosinophil cationic protein and myeloperoxidase in nasal secretion as markers of inflammation in allergic rhinitis. Allergy 1987;42:583590.
  • 20
    Venge P, Dahl R. Are blood eosinophil number and activity important for the development of the late asthmatic reaction after challenge? Eur Respir J 1989;6:430434.
  • 21
    Wardlaw A. Eosinophil density: what does it mean? Clin Exp Allergy 1995;25:11451149.
  • 22
    Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet activating factor is a potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986;78:17011706.
  • 23
    Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Waltman P, Kay AB. Interleukin 5 (IL-5) selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic donors. Blood 1992;79:29522959.
  • 24
    Tomassini M, Magrini L, De Petrillo G, et al. Serum levels of eosinophil cationic protein in allergic disease and natural allergen exposure. J Allergy Clin Immunol 1996;97:13501355.
  • 25
    Warringa RAJ, Mengelers HJJ, Raaijmakers JAM, Bruijnzeel PLB, Koenderman L. Upregulation of formylpeptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma. J Allergy Clin Immunol 1993;91:11981205.
  • 26
    Rogenes P, Van As A, Kral K. Fluticasone propionate 200 µg once a day relieves symptoms of allergic rhinitis within 24 to 48 hours. Allergy Clin Immunol News 1991;Suppl 1 (Abstract 942).
  • 27
    Wang D, Duyck F, Smitz J, Clement P. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy 1998;53:375382.
  • 28
    Juliusson S, Holmberg K, Karlsson G, Enerbäck L, Pipkorn U. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Clin Exp Allergy 1993;23:591599.
  • 29
    Locewicz S, Wang J, Duddle J, et al. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract. J Allergy Clin Immunol 1992;89:951957.
  • 30
    Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. J Clin Invest 1988;81:237.
  • 31
    Djukanovic R, Wilson JW, Britten JM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669674.